Vaishali Pharma LimitedVAISHALICorporate

Pharmaceuticals Latest results: Jun 2026 4 quarters of data

₹7.81

MCap ₹102 Cr · P/E 22.8

Vaishali Pharma Limited — Stock analysis & AI research Vaishali Pharma Limited — Seasonality — best & worst months Vaishali Pharma Limited — Technical setup — score, trend, support & resistance Vaishali Pharma Limited — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹23 Cr

Sales · Jun 2026

₹1 Cr

Operating Profit · Jun 2026

6.5%

OPM % · Jun 2026

₹2 Cr

Net Profit · Jun 2026

₹0.12

EPS · Jun 2026

📝 Vaishali Pharma Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Vaishali Pharma Limited reported revenue of ₹23 crore for the quarter ended June 2026 (Q1 FY27), and down 15.0% sequentially over the March 2026 quarter.

Net profit stood at ₹2 crore. Earnings per share (EPS) came in at ₹0.12.

Operating profit stood at ₹1 crore — an operating margin (OPM) of 6.5%.

Full year and trailing twelve months

For the full year FY26, Vaishali Pharma Limited posted revenue of ₹85 crore, with a net profit of ₹3 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹108 crore with a net profit of ₹4 crore.

Valuation snapshot

At the current price of ₹7.81, VAISHALI has a market capitalisation of ₹102 crore and a trailing P/E of about 22.8.

Within the Pharmaceuticals industry, it is the 25th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Jul 2026, promoters held 30.54%, public shareholders 69.46% of Vaishali Pharma Limited.

Promoter holding slipped from 31.61% to 30.54% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹102 Cr

Current Price ?

₹7.8

P/E ?

22.81above ind

Industry P/E ?

22.40

P/B ?

1.48

P/S ?

0.94

P/FCF ?

N/A

Enterprise Value ?

₹121 Cr

EV/EBITDA ?

28.54

PEG ?

N/A

Earnings Yield ?

3.0%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹108 Cr

OPM ?

3.9%

Profit after tax (TTM) ?

₹4 Cr

EPS (TTM) ?

₹0.34

ROCE ?

N/A

ROE ?

6.5%

ROA ?

3.6%

Growth

Sales — latest qtr ?

₹23 Cr

PAT — latest qtr ?

₹2 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹19 Cr

Debt to Equity ?

0.28

Interest Coverage ?

1.4

Current Ratio ?

N/A

Ownership

Promoter holding ?

30.54%

Change in promoter holding ?

4.22%

Pledged percentage ?

N/A

Market

Return 3 months ?

-0.4%

Return 6 months ?

1.3%

🗓️ Quarterly results (4 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	33	25	27	23	—	-15.0%
Operating Profit	1	2	-0	1	—	+842.6%
Other Income	1	1	1	1	—	-54.0%
Interest	0	1	1	0	—	-72.7%
Depreciation	0	0	0	0	—	-14.6%
Profit Before Tax	2	2	0	2	—	+862.3%
Net Profit	1	1	0	2	—	+277.1%
EPS	0.09	0.10	0.03	0.12	—	+300.0%
OPM %	4.2%	6.3%	-0.7%	6.5%	—	+1028.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	Prev FY	FY26	TTM	YoY %
Sales	—	₹85 Cr	₹108 Cr	—
Operating Profit	—	₹3 Cr	₹4 Cr	—
OPM %	—	3.23%	3.92%	—
NPM %	—	3.43%	4.14%	—
Other Income	—	₹3 Cr	₹4 Cr	—
Depreciation	—	₹0 Cr	₹1 Cr	—
Interest	—	₹2 Cr	₹2 Cr	—
EBIT	—	₹2 Cr	₹4 Cr	—
PBT	—	₹4 Cr	₹5 Cr	—
Tax	—	—	₹0 Cr	—
Net Profit	—	₹3 Cr	₹4 Cr	—
EPS	—	₹0.22	₹0.34	—
Material Cost	—	—	₹17 Cr	—
Employee Cost	—	—	₹1 Cr	—
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 1 periods)

Metric	Mar 2026	% Chg
Equity Capital	26	—
Reserves	43	—
Borrowings	19	—
Other Liabilities	35	—
Total Liabilities	123	—
Fixed Assets	2	—
CWIP	0	—
Investments	6	—
Other Assets	116	—
Total Assets	123	—

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	1	1	-18	0	+100.0%
Cash from Investing Activity	0	1	-0	-5	—
Cash from Financing Activity	-2	-1	18	5	-72.2%
Net Cash Flow	-0	1	0	-0	—
Free Cash Flow	1	1	-18	-0	+100.0%
CFO/OP	28%	185%	-3,104%	19%	+100.6%

➗ Ratios (latest 1 periods)

Metric	Mar 2026	% Chg
Debtor Days	170	—
Inventory Days	13	—
Days Payable	81	—
Cash Conversion Cycle	102	—
Working Capital Days	212	—

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Jul 2026	% Chg
Promoters	26.32%	26.32%	31.61%	31.61%	31.61%	30.54%	-3.4%
Public	73.68%	73.68%	68.39%	68.39%	68.39%	69.46%	+1.6%
No. of Shareholders	28,682	27,752	27,148	26,534	26,671	26,697	+0.1%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUDEEPPHRM Sudeep Pharma	₹1,033.30	11,671	63.3	675	184	34.6%	27.3%	—	—	26.6%	30.9%
2	SPARC Sun Pharma	₹185.08	6,006	3.8	1,909	1,584	84.7%	83.0%	2512.3%	553.9%	314.1%	59.9%
3	GUJTHEM Gujarat Themis	₹412.60	5,370	92.3	173	48	47.3%	27.8%	8.6%	-6.1%	21.6%	23.0%
4	539997 Kwality Pharmaceuticals	₹2,652.10	3,525	34.0	553	81	24.4%	14.6%	35.7%	71.8%	46.3%	113.5%
5	524632 Shukra Pharmaceuticals	₹80.95	2,403	99.9	75	36	65.0%	48.2%	74.0%	130.1%	336.4%	1359.2%
6	FERMENTA Fermenta Biotech	₹475.00	1,362	21.4	501	64	18.9%	12.7%	—	—	-17.9%	-30.6%
7	506414 Fermenta Biotech	₹552.60	1,313	27.2	511	59	17.6%	11.5%	11.9%	-6.6%	-10.4%	-56.7%
8	AHCL Anlon Healthcare	₹20.20	1,074	—	—	—	—	—	—	—	163.0%	133.3%
9	541096 Bharat Parenterals	₹1,525.00	1,062	—	323	-30	3.3%	-9.3%	1.5%	37.5%	-19.2%	-309.6%
10	540737 Shree Ganesh	₹796.30	855	66.2	99	15	31.4%	15.6%	0.7%	-23.0%	-41.8%	-67.5%
11	AMANTA Amanta Healthcare	₹197.75	768	52.5	291	15	20.4%	5.0%	—	—	5.4%	-5.6%
12	539730 Fredun Pharmaceuticals	₹827.85	611	10.3	747	44	14.7%	5.9%	40.1%	90.0%	90.2%	88.1%
13	500422 Transchem Ltd-$	₹38.00	474	10.8	—	4	—	—	-100.0%	-17.8%	-100.0%	186.3%
14	HALEOSLABS Haleos Labs	₹1,525.00	461	21.0	324	15	12.6%	4.7%	-3.2%	-4.9%	-11.6%	-58.0%
15	524731 Jenburkt Pharmaceuticals	₹865.75	404	11.6	170	33	23.6%	19.4%	11.8%	6.1%	-1.4%	-26.4%
16	543616 Trident Lifeline	₹279.85	364	14.0	134	24	24.6%	17.9%	—	—	42.6%	44.2%
17	512600 Astal Laboratories	₹75.00	308	32.3	170	10	8.8%	5.7%	142.9%	-9.0%	56.0%	77.4%
18	524828 BDH Industries	₹336.80	300	16.6	100	12	15.3%	11.7%	44.3%	16.6%	20.2%	48.8%
19	500009 Ambalal Sarabhai	₹38.73	297	21.9	206	14	7.1%	6.6%	3.1%	261.1%	8.0%	-51.6%
20	532039 Zenotech Laboratories	₹64.90	263	—	45	-3	17.0%	-5.6%	1.3%	-119.2%	10.1%	-146.0%
21	531739 Gennex Laboratories	₹13.87	255	19.0	183	21	14.4%	11.3%	24.9%	15.5%	16.6%	-6.9%
22	524790 Everest Organics	₹159.20	252	29.4	191	5	10.3%	2.8%	23.0%	527.7%	-10.0%	-21.1%
23	530163 Kerala Ayurveda	₹310.20	225	—	125	-26	-14.9%	-20.8%	9.0%	-16.8%	-21.3%	-477.8%
24	531569 Sanjivani Paranteral	₹199.95	214	32.7	66	7	15.3%	11.3%	-7.6%	-14.4%	8.8%	32.7%
25	VAISHALI Vaishali Pharma	₹8.16	106	25.5	108	4	3.9%	3.9%	9.8%	391.5%	-3.6%	16.4%

❓ Frequently asked questions

What was Vaishali Pharma Limited's revenue in Q1 FY27?